title: The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology
design: For targeted DNA sequencing, two gene panels were used for targeting DNA sequencing of distinct PDX samples. The first platform, denoted as the Garvan panel, is a cancer gene sequencing panel (PV2) designed through Roche/Nimblegen spanning 633 cancer-associated genes (2.01 Mb target region). The second platform, denoted as the Twist panel, is a custom gene capture panel from Twist Biosciences targeting a total of 2.13 Mb of exonic sequence from 16,875 regions in 662 genes. It includes all genes from the Garvan panel, and 29 additional genes of interest. Hybridization capture and library preparation were performed in batches of 8 according to the manufacturer's instructions with the exception of fragmentation time, which was reduced to 16 min. Libraries were barcoded and sequenced on the Illumina NextSeq platform using 75 bp paired-end reads.